Follow BIIB's trial news. Pro members can get an alert when Biogen files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 63% in a year while the S&P 500 rose 12%.
“The increase in rare disease product revenue was primarily due to our new product launches”
| Free cash flow nearly doubled | $1.14B → $2.05B in 3 years |
| Latest filing | 8-K, Oct 28 |
Tue Nov 17: Jefferies 17th Annual London Global…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed +3.2% on average, higher 3 of 4 times.
Director Lloyd Minor sold 1,186 shares on Aug 4, under a planned sale. 3 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Excellentfor quality, not price, 7 of 14 chart checks firingWhat the Quality Score means
BIIB is #24 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 24 |
Share count against a year before: BIIB +0.8%, SRRK +16%, EXEL -8.1%, CRSP +6%.
Expected to report Fri Feb 5, before the open (in 87 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $2.8B, 11% more than a year ago; a loss of $0.14 a share.
“GAAP diluted EPS of $(0.14) driven primarily by transaction-related charges; Non-GAAP diluted EPS of $2.62, reflecting $284 million of acquired IPR&D, upfront and milestone expense”
| Line | Q3 2026 | Q3 2025 |
|---|---|---|
| Product | $2.1B | $1.8B |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 28)
| Measure | Figure |
|---|---|
| Non-GAAP diluted EPS (reported range) | $12.20 to $13.00 |
“The increase in third quarter 2026 GAAP and Non-GAAP SG&A was primarily due to the inclusion of the commercial and management operations of Apellis and an increase in operational spending on sales and marketing activities in support of our U.S. and international product launches.”
From its results filing (SEC filing · Oct 28)
Sales fell 6% a year over 5 years, fiscal 2020 to 2025.
Its share count fell 1.8% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 28, 2026 | -3.1% | -3.4% | -1.5% |
| Jul 29, 2026 | +2.4% | +1.8% | +1.4% |
| Apr 29, 2026 | -0.1% | +6.0% | +3.1% |
Sales grew in two of the last seven years, to $9.9B in 2025. It made a profit in each of the eight years.
RSI 59.8, MACD below signal, above both averages. Not scored.
16 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: BIIB is under 0.1% of VOO, under 0.1% of IVV, and under 0.1% of SPY, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026 (SPY's as filed by IVV).
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
“Competition in the biopharmaceutical industry and the markets in which we operate is intense.”
BIIB scores 15 today, which Breakaway calls Excellent. It is #24 of 281 in Biotech by Quality Score, with 7 of 14 chart checks firing. Up 63% in a year while the S&P 500 rose 12%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BIIB scores 15 today, which Breakaway calls Excellent (15 to 19). That is #24 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BIIB's 15.
Expected to report Fri Feb 5, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. BIIB closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.